Annie Druet-Cabanac, Jessica Azzi, Marco Lucchino, Virginie Simon, Lucile Offredo, Jean-Baptiste Briere, Sean Hood
{"title":"广泛性焦虑障碍:流行病学、负担和共病抑郁症。","authors":"Annie Druet-Cabanac, Jessica Azzi, Marco Lucchino, Virginie Simon, Lucile Offredo, Jean-Baptiste Briere, Sean Hood","doi":"10.1080/03007995.2025.2529974","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>Generalized anxiety disorder (GAD) is a common long-term psychiatric disorder with varying prevalence in epidemiological studies. The burden of GAD is high and associated risk factors are not well documented in the general population.</p><p><strong>Methods: </strong>This observational retrospective study of US adult patients with GAD used Optum's de-identified Clinformatics Data Mart Database to explore epidemiology, patient characteristics, risk factors, and disease burden. Adults with GAD were matched with a control general population.</p><p><strong>Results: </strong>A total of 1,086,618 US patients with GAD were included: mean patient age was 49.4 ± 19.1 years and 66.5% were female. Incidence of GAD increased from 0.8% in 2012 to 2.4% in 2022. One-year prevalence of GAD increased from 2.1% in 2012 to 7.4% in 2022. Individuals with GAD utilized healthcare resources more frequently than the matched control population. Retrospectively-assessed risk factors most associated with GAD were pre-existing major depressive disorder (odds ratio [OR] 5.06; 95% confidence interval [CI]: 5.03, 5.08; <i>p</i> < 0.001), family problems (OR 2.83 95% CI: 2.76, 2.89; <i>p</i> < 0.001), SARS-CoV-2 infection (OR 2.53; 95% CI: 2.48, 2.57; <i>p</i> < 0.001), employment difficulties (OR 2.48; 95% CI: 2.36, 2.60; <i>p</i> < 0.01), and attention deficit hyperactivity disorder (OR 2.19; 95% CI: 2.17, 2.21; <i>p</i> < 0.001).</p><p><strong>Conclusion: </strong>Risk factors, particularly depressive symptoms, should be acknowledged during the diagnosis and management of patients with GAD to support optimal clinical outcomes.</p>","PeriodicalId":10814,"journal":{"name":"Current Medical Research and Opinion","volume":" ","pages":"1-12"},"PeriodicalIF":2.4000,"publicationDate":"2025-07-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Generalized anxiety disorder: epidemiology, burden, and comorbid depression.\",\"authors\":\"Annie Druet-Cabanac, Jessica Azzi, Marco Lucchino, Virginie Simon, Lucile Offredo, Jean-Baptiste Briere, Sean Hood\",\"doi\":\"10.1080/03007995.2025.2529974\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objective: </strong>Generalized anxiety disorder (GAD) is a common long-term psychiatric disorder with varying prevalence in epidemiological studies. The burden of GAD is high and associated risk factors are not well documented in the general population.</p><p><strong>Methods: </strong>This observational retrospective study of US adult patients with GAD used Optum's de-identified Clinformatics Data Mart Database to explore epidemiology, patient characteristics, risk factors, and disease burden. Adults with GAD were matched with a control general population.</p><p><strong>Results: </strong>A total of 1,086,618 US patients with GAD were included: mean patient age was 49.4 ± 19.1 years and 66.5% were female. Incidence of GAD increased from 0.8% in 2012 to 2.4% in 2022. One-year prevalence of GAD increased from 2.1% in 2012 to 7.4% in 2022. Individuals with GAD utilized healthcare resources more frequently than the matched control population. Retrospectively-assessed risk factors most associated with GAD were pre-existing major depressive disorder (odds ratio [OR] 5.06; 95% confidence interval [CI]: 5.03, 5.08; <i>p</i> < 0.001), family problems (OR 2.83 95% CI: 2.76, 2.89; <i>p</i> < 0.001), SARS-CoV-2 infection (OR 2.53; 95% CI: 2.48, 2.57; <i>p</i> < 0.001), employment difficulties (OR 2.48; 95% CI: 2.36, 2.60; <i>p</i> < 0.01), and attention deficit hyperactivity disorder (OR 2.19; 95% CI: 2.17, 2.21; <i>p</i> < 0.001).</p><p><strong>Conclusion: </strong>Risk factors, particularly depressive symptoms, should be acknowledged during the diagnosis and management of patients with GAD to support optimal clinical outcomes.</p>\",\"PeriodicalId\":10814,\"journal\":{\"name\":\"Current Medical Research and Opinion\",\"volume\":\" \",\"pages\":\"1-12\"},\"PeriodicalIF\":2.4000,\"publicationDate\":\"2025-07-10\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Current Medical Research and Opinion\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/03007995.2025.2529974\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"MEDICINE, GENERAL & INTERNAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Medical Research and Opinion","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/03007995.2025.2529974","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
Generalized anxiety disorder: epidemiology, burden, and comorbid depression.
Objective: Generalized anxiety disorder (GAD) is a common long-term psychiatric disorder with varying prevalence in epidemiological studies. The burden of GAD is high and associated risk factors are not well documented in the general population.
Methods: This observational retrospective study of US adult patients with GAD used Optum's de-identified Clinformatics Data Mart Database to explore epidemiology, patient characteristics, risk factors, and disease burden. Adults with GAD were matched with a control general population.
Results: A total of 1,086,618 US patients with GAD were included: mean patient age was 49.4 ± 19.1 years and 66.5% were female. Incidence of GAD increased from 0.8% in 2012 to 2.4% in 2022. One-year prevalence of GAD increased from 2.1% in 2012 to 7.4% in 2022. Individuals with GAD utilized healthcare resources more frequently than the matched control population. Retrospectively-assessed risk factors most associated with GAD were pre-existing major depressive disorder (odds ratio [OR] 5.06; 95% confidence interval [CI]: 5.03, 5.08; p < 0.001), family problems (OR 2.83 95% CI: 2.76, 2.89; p < 0.001), SARS-CoV-2 infection (OR 2.53; 95% CI: 2.48, 2.57; p < 0.001), employment difficulties (OR 2.48; 95% CI: 2.36, 2.60; p < 0.01), and attention deficit hyperactivity disorder (OR 2.19; 95% CI: 2.17, 2.21; p < 0.001).
Conclusion: Risk factors, particularly depressive symptoms, should be acknowledged during the diagnosis and management of patients with GAD to support optimal clinical outcomes.
期刊介绍:
Current Medical Research and Opinion is a MEDLINE-indexed, peer-reviewed, international journal for the rapid publication of original research on new and existing drugs and therapies, Phase II-IV studies, and post-marketing investigations. Equivalence, safety and efficacy/effectiveness studies are especially encouraged. Preclinical, Phase I, pharmacoeconomic, outcomes and quality of life studies may also be considered if there is clear clinical relevance